CXCL8在肿瘤耐药中的作用

Roles of CXCL8 in tumor drug resistance

肿瘤耐药是影响疾病进程和患者预后的主要因素。CXC趋化因子配体8(CXC chemokine ligand8,CXCL8)又称为白细胞介素-8(interleukin-8,IL-8),是具有趋化作用的细胞因子,是肿瘤微环境的重要成员。CXCL8在多种肿瘤患者的循环和组织中表达升高,与药物疗效和预后有相关性。CXCL8主要通过招募细胞浸润、诱导肿瘤细胞上皮-间质转化(epithelial-mesenchymal transition,EMT)获得干性特征,还能通过促进血管生成等多途径降低药物的应答效力。本文概述了CXCL8在肿瘤耐药形成中的作用,为建立疗效监测指标、制订联合治疗方案提供重要的理论基础和实验依据。

Tumor drug resistance is a leading factor of disease progression and patient prognosis.CXC chemokine ligand 8(CXCL8),also known as interleukin-8(IL-8),is a chemotactic cytokine and an important member of the tumor microenvironment.The expression level of CXCL8 in peripheral blood and tissues was increased in many malignant tumors and it is associated with drug efficacy and prognosis.CXCL8 can induce drug resistance by recruiting cell infiltration and promoting the process of epithelial-to-mesenchymal transition(EMT),cancer stem-like properties,as well as angiogenesis in tumor cells.This review focuses on the roles of CXCL8 in cancer drug resistance and offers theoretical and experimental bases for its translational applications as a biomarker to monitor efficacy and develop combination treatment regimens.